Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H19NO3 |
Molecular Weight | 237.2954 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOc1ccccc1OCC2CNCCO2
InChI
InChIKey=YWPHCCPCQOJSGZ-UHFFFAOYSA-N
InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3
Molecular Formula | C13H19NO3 |
Molecular Weight | 237.2954 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580 |
|||
Target ID: P23975 Gene ID: 6530.0 Gene Symbol: SLC6A2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27230580 |
PubMed
Title | Date | PubMed |
---|---|---|
Contribution of sleep research to the development of new antidepressants. | 2005 |
|
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. | 2005 |
|
Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome. | 2005 Sep |
|
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
|
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. | 2006 Oct 20 |
|
Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma. | 2007 Dec 28 |
|
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood. | 2007 May |
|
Antidepressant drugs for narcolepsy. | 2008 Jan 23 |
|
Narcolepsy: current treatment options and future approaches. | 2008 Jun |
|
Adjustment Disorder: epidemiology, diagnosis and treatment. | 2009 Jun 26 |
|
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry. | 2009 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22454923
100 mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 23:08:57 UTC 2021
by
admin
on
Fri Jun 25 23:08:57 UTC 2021
|
Record UNII |
5I5Y2789ZF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N06AX09
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
||
|
WHO-VATC |
QN06AX09
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5I5Y2789ZF
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
M11448
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | Merck Index | ||
|
3489
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
DB09185
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
CHEMBL306700
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
VILOXAZINE
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
256-281-7
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
46817-91-8
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
D014745
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
46817-91-8
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
11196
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | RxNorm | ||
|
2820
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
5666
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
SUB00049MIG
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY | |||
|
C152877
Created by
admin on Fri Jun 25 23:08:57 UTC 2021 , Edited by admin on Fri Jun 25 23:08:57 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |